JMP Securities raises Pharvaris stock target to $55

Wolleben’s updated price target is a reflection of a revised revenue forecast for Pharvaris’s prophylactic treatment, aligning it with market models for other companies in the same space, such as Attune Pharmaceuticals, Inc. and BioCryst Pharmaceuticals , Inc. (NASDAQ: NASDAQ:BCRX). The adjustment also considers a larger addressable patient population, which contributes to the new $55 risk-adjusted, Discounted Cash Flow (DCF)-derived price target. The stock shows unique market behavior with a beta of -3.06, indicating it often moves contrary to broader market trends. Subscribers to InvestingPro can access 6 additional investment tips and comprehensive financial metrics for deeper analysis. The stock shows unique market behavior with a beta of -3.06, indicating it often moves contrary to broader market trends. Subscribers to InvestingPro can access 6 additional investment tips and comprehensive financial metrics for deeper analysis. Wolleben’s updated price target is a reflection of a revised revenue forecast for Pharvaris’s prophylactic treatment, aligning it with market models for other companies in the same space, such as Attune Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). The adjustment also considers a larger addressable patient population, which contributes to the new $55 risk-adjusted, Discounted Cash Flow (DCF)-derived price target. The stock shows unique market behavior with a beta of -3.06, indicating it often moves contrary to broader market trends. Subscribers to InvestingPro can access 6 additional investment tips and comprehensive financial metrics for deeper analysis.

Pharvaris’s deucrictibant is noted to share the same mechanism of action as icatibant, the most commonly used on-demand drug for HAE treatment. According to Wolleben, doctors believe patients will favor deucrictibant over KalVista Pharmaceuticals, Inc.’s (NASDAQ: NASDAQ:KALV) sebetralstat, should both receive approval.

The analyst also pointed out the potential of Pharvaris’s extended-release version of deucrictibant to capture a significant share of the prophylactic market. This optimism is based on the expectation that the Phase 3 results will echo the promising data observed in Phase 2 trials.

Wolleben’s updated price target is a reflection of a revised revenue forecast for Pharvaris’s prophylactic treatment, aligning it with market models for other companies in the same space, such as Attune Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). The adjustment also considers a larger addressable patient population, which contributes to the new $55 risk-adjusted, Discounted Cash Flow (DCF)-derived price target.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.